Androgen-regulated PMEPA1 gene and polypeptides
First Claim
Patent Images
1. A method of diagnosing prostate cancer, comprising determining the expression of an androgen-regulated gene in a biological sample comprising prostate cells, wherein the androgen-regulated gene is PMEPA1, wherein expression of the PMEPA1 gene is determined by measuring the level of expression of a PMEPA1 nucleotide sequence comprising SEQ ID NO:
- 2 in the biological sample, and wherein reduced expression of the PMEPA1 gene in the biological sample as compared to a control sample comprising noncancerous prostate cells correlates with an increased probability for the presence of prostate cancer.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.
-
Citations
11 Claims
-
1. A method of diagnosing prostate cancer, comprising determining the expression of an androgen-regulated gene in a biological sample comprising prostate cells, wherein the androgen-regulated gene is PMEPA1, wherein expression of the PMEPA1 gene is determined by measuring the level of expression of a PMEPA1 nucleotide sequence comprising SEQ ID NO:
- 2 in the biological sample, and wherein reduced expression of the PMEPA1 gene in the biological sample as compared to a control sample comprising noncancerous prostate cells correlates with an increased probability for the presence of prostate cancer.
- View Dependent Claims (2, 3, 4, 5)
-
6. A method of prognosing the pathologic stage of prostate cancer in a patient, comprising determining the expression of an androgen regulated gene in a biological sample comprising prostate cells, wherein the androgen-regulated gene is PMEPA1, wherein expression of the PMEPA1 gene is determined by measuring the level of expression of a PMEPA1 nucleotide sequence comprising SEQ ID NO:
- 2 in the biological sample, and wherein reduced expression of the PMEPA1 gene in the biological sample as compared to a control sample comprising noncancerous prostate cells correlates with an increased probability for advanced prostate cancer, wherein the advanced prostate cancer is characterized by at least pathological T3 disease.
- View Dependent Claims (7, 8, 9, 10, 11)
Specification